In general terms, DAPK methylation can serve as an early biomarker for both diagnosis and prognosis in patients with NSCLC, such as those identified in NSCLC patients' sputum samples and/or serum samples.119. The gene discussed is DAPK1; the disease is non-small cell lung carcinoma.